Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pekarin
- Development stage
- Preclinical
- Lead developer
- BlueSky Immunotherapies
- Modality
- Vaccines & Immunotherapeutics
01
Overview
**Pekarin** is a preclinical biological vaccine program developed by BlueSky Immunotherapies for prevention of COVID-19 and influenza. Public pipeline listings identify the program and its infectious-disease indications, but do not disclose its antigen composition, vaccine platform, adjuvant, route of administration, or molecular mechanism of action. ([synapse.patsnap.com](https://synapse.patsnap.com/organization/aa2db43961d8d78fb6aa8112033ae1e2))
- Other names
- Pekarin
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on Pekarin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pekarin.